KDM4A and prostate carcinoma: Because mutation of JMJD2A methylation sites in the androgen-independent DU145 cells severely compromised their oncogenicity, the present study strongly suggests an additional potential utility of SET7/9 inhibitors for castration-resistant prostate cancer.